Cocrystal Pharma Inc (COCP)
$1.7
Performance
- $1.69$1.81$1.70
0.59%
Downside
Day's Volatility :6.63%
Upside
6.08%
- $1.33$3.10$1.70
22.06%
Downside
52 Weeks Volatility :57.26%
Upside
45.16%
Returns
| Period | Cocrystal Pharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -32.81% | 0.0% |
6 Months | 15.65% | 0.0% |
1 Year | -21.3% | 0.0% |
3 Years | -87.46% | -22.3% |
Highlights
Market Capitalization | 17.3M |
Book Value | $1.71 |
Earnings Per Share (EPS) | -1.75 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -46.06% |
Return On Equity TTM | -68.86% |
Revenue TTM | 510.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 26.900000000000002% |
Gross Profit TTM | -8.8M |
EBITDA | -21.2M |
Diluted Eps TTM | -1.75 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.94 |
EPS Estimate Next Year | -2.21 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.5 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 370.59%
Technicals Summary
Sell
Neutral
Buy
Cocrystal Pharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cocrystal Pharma Inc | -2.3% | 15.65% | -21.3% | -87.46% | -91.83% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cocrystal Pharma Inc | NA | NA | 0.0 | -1.94 | -0.69 | -0.46 | NA | 1.71 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cocrystal Pharma Inc | Buy | $17.3M | -91.83% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Cocrystal Pharma Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 58.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 156.7%
Institutional Holdings
Vanguard Group Inc
2.71%Renaissance Technologies Corp
1.24%BlackRock Inc
0.72%Geode Capital Management, LLC
0.59%Morgan Stanley - Brokerage Accounts
0.58%Susquehanna International Group, LLP
0.51%
Company Information
cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.
Organization | Cocrystal Pharma Inc |
Employees | 12 |
CEO | Dr. Roger D. Kornberg Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.70
-5.03%
Keyarch Acquisition Corp
$1.70
-5.03%
Connexa Sports Technologies Inc
$1.70
-5.03%
Us Value Etf
$1.70
-5.03%
First Wave Biopharma Inc
$1.70
-5.03%
Global X Msci Next Emerging
$1.70
-5.03%
Fat Projects Acquisition Corp
$1.70
-5.03%
Capital Link Global Fintech
$1.70
-5.03%
Applied Uv Inc
$1.70
-5.03%